What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Cancer. Intervention: Sodium-glucose cotransporter-2 inhibitors (SGLT2i). Primary outcome: All-cause mortality and an HF composite (new-onset HF and/or HF hospitalization) (p=<0.001).

May 17, 2026Open Access

SGLT2 Inhibitors in Cardio-Oncology

Q: What are the key findings of this study?

In adult patients with cancer, SGLT2 inhibitors were associated with fewer deaths and heart failure events, although substantial heterogeneity was observed across studies (P < 0.001).

Q: What question did this study set out to answer?

The study aims to assess whether SGLT2 inhibitors reduce all-cause mortality and heart failure in cancer patients receiving chemotherapy.

Resultado clave

In adult patients with cancer, SGLT2 inhibitors were associated with fewer deaths and heart failure events, although substantial heterogeneity was observed across studies (P < 0.001).

Puntos clave

The study aims to assess whether SGLT2 inhibitors reduce all-cause mortality and heart failure in cancer patients receiving chemotherapy.
Conducted a systematic search of PubMed, Cochrane CENTRAL, and Embase for studies involving SGLT2 inhibitors in cancer patients.
Utilized random-effects models to analyze their effects on mortality and heart failure outcomes in patients over 18 years.
Performed meta-regression to explore factors that might influence these outcomes, such as age and use of other cardiovascular medications.
SGLT2 inhibitors were linked to a significant reduction in deaths and heart failure events among cancer patients (overall effect size 66.4%; P < 0.001).
No increased safety concerns were identified for patients receiving SGLT2 inhibitors.
Substantial heterogeneity was observed across included studies.

Diseño del estudio

Tipo

Meta-Analysis

PICO estructurado

Does SGLT2 inhibitors reduce all-cause mortality and heart failure outcomes in adult patients with cancer?

Población

Adult patients (>18 years) with cancer

Intervención

Sodium-glucose cotransporter-2 inhibitors (SGLT2i)

Resultado

All-cause mortality and an HF composite (new-onset HF and/or HF hospitalization)composite

In adult cancer patients, SGLT2 inhibitors appear safe and may be associated with reduced mortality and heart failure events, though randomized trials are needed to confirm these findings.

Resultado numérico

valor p: p=<0.001

Limitaciones

Substantial heterogeneity was observed across studies
Findings are hypothesis-generating and require confirmation by randomized controlled trials

Resumen

BACKGROUND: According to available evidence, sodium-glucose cotransporter-2 inhibitors (SGLT2i) may confer cardioprotection in patients with cancer undergoing chemotherapy. OBJECTIVES: The objective of the study was to evaluate the impact of SGLT2i on all-cause mortality and heart failure (HF) outcomes in this population. METHODS: We searched PubMed, Cochrane CENTRAL, and Embase through August 2025 for studies of SGLT2i in adult patients with cancer. Random-effects models were used to pool effects for all-cause mortality and an HF composite (new-onset HF and/or HF hospitalization) in cancer patients >18 years. Meta-regression tested effect modification by beta-blockers, statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, age, and sex. RESULTS: = 66.4%; P < 0.001). Safety outcomes were not increased in the SGLT2i arm. CONCLUSIONS: In patients with cancer, SGLT2i appear safe and are associated with fewer deaths and HF events, although substantial heterogeneity was observed across studies. Randomized controlled trials are warranted to confirm these hypothesis-generating findings.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo